Video Interview: This Biotech Wants to Take Over the NOTCH Space
Cellestia, based in Basel, is a biotech spin-off from EPFL, developing new compounds targeting the…
Cellestia, based in Basel, is a biotech spin-off from EPFL, developing new compounds targeting the…
Rigontec has announced the start if its first-in-human Phase I/II study with its pioneering RNA-based…
Imcheck Therapeutics from Marseille has just completed a €20M Series A funding round, backed by big investors like…
As immunotherapies are moving from large academic centers to clinics across the world, doctors are…
At our second meetup in Basel last week, Philip had the chance to talk to…
Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T…
Located in the charming town of Utrecht in the Netherlands, Ntrans Technologies was newly founded in…
Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune…
Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring…
A new study published in the journal Science Translational Medicine identifies a new treatment strategy…
A new report has listed the world’s most expensive drugs. Not surprisingly, those targeting rare…
The small village of Keele is probably best known for its university, but it also…